肿瘤分子靶向治疗药物的应用进展(4)
[13]Seidman AD，Berry D，Cirrincione C，et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer，with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors：final results of Cancer and Leukemia Group B Protocol 9840[J].J Clin Oncol ......
您现在查看是摘要页，全文长 2257 字符。